Newborn Screening Industry

The global newborn screening market size was valued at USD 789.35 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.54% from 2023 to 2030.The rising neonatal population, increasing cases of congenital diseases in newborns, growing consumer awareness, and favorable initiatives & support from various governments organizing several programs & legislations are factors estimated to propel market growth over the forecast period. In addition, technological advancements in screening methodologies are also expected to boost the market.

The extensively growing prevalence of congenital diseases in newborns is expected to have a positive impact on the market growth for newborn screening. According to data published by the WHO in February 2023, an estimated 240,000 newborns die within 28 days of birth each year globally due to congenital diseases. Congenital disorders are further responsible for an estimated 170,000 child deaths aged between 1 month and 5 years.

Gather more insights about the market drivers, restrains and growth of the Global Newborn Screening market

Newborn Screening Market Segments Highlights:

Technology Insights

In 2022, the tandem mass spectrometry segment dominated the market for newborn screening with 24.5% of the revenue share, owing to its cost-effectiveness, higher applicability, and technological upgrades. The tandem mass spectrometry (MS/MS) segment is also likely to expand at a substantial CAGR due to its high efficiency in diagnosing an array of conditions in a single procedure. Furthermore, the development of market players with respect to new products is also expected to accelerate segment growth by 2030. For instance, in April 2023, Waters Corporation announced the launch of its new Xevo TQ Absolute IVD Mass Spectrometer for clinical applications.

Test Type Insights

Dry blood spot tests dominated the overall newborn screening market, accounting for over 45.9% of the revenue share in 2022. Moreover, the segment is expected to expand at the fastest CAGR over the forecast period. The DBS test is used for the detection of over 50 conditions that are associated with newborn screening. The growing number of initiatives by government authorities are also projected to accelerate segment growth during the forecast period. For instance, in March 2022, the U.K.-based Oxford University announced the launch of its first pilot study for the diagnosis of spinal muscular atrophy.

Product Insights

The instruments segment held the dominant share of 75.91% in the market for newborn screening in 2022 and is expected to advance at the fastest CAGR over the forecast period. The growing number of newborn screening procedures, rising awareness about early disease detection, and increasing investments for newborn screening are estimated to drive the instrument segment during the forecast period. In March 2023, GC Labs announced the launch of its new test for diagnosis of Inborn Errors of Metabolism (IEM) amongst newborns with the incorporation of improved disease detection methods.

Regional Insights

Asia Pacific accounted for the largest share in the market for newborn screening in 2022, accounting for around 32.90% of the revenue share. Factors such as improving infrastructure and healthcare plans and the availability of new opportunities for expansion are expected to play a major role in driving industry demand over the forecast period. Moreover, owing to the high population density, higher birth rate, and soaring prevalence of congenital diseases, Asia Pacific is expected to be the fastest-growing market for newborn screening techniques.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global ovarian cancer diagnostics market was valued at USD 4.60 billion in 2023 and is expected to grow at a CAGR of 5.0% during the forecast period. Increasing prevalence of ovarian cancer and increased emphasis on early diagnosis and treatment are the key factors expected to drive market growth.
• The global infectious disease molecular diagnostics market size was valued at USD 52.0 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2030.

Key Companies & Market Share Insights

The industry players are actively involved in strategic partnerships and mergers & acquisitions in order to ensure sustainability. For example, Trivitron Healthcare and Agilent Technologies have partnered to initiate collaboration in the area of high-precision in-vitro diagnostics based on the LC-MS/MS platform. Furthermore, in January 2023, Masimo announced the launch of its new state-of-the-art baby monitoring system. This newly introduced system allows caretakers to monitor the data of babies in real time. Some of the prominent players in the global newborn screening market include:

• Bio-Rad Laboratories
• Agilent Technologies
• Covidien plc
• Masimo
• Waters Corporation
• Natus Medical
• Trivitron Healthcare
• GE Lifesciences
• PerkinElmer Inc
• AB SCIEX

Segments Covered in the Report

Grand View Research has segmented the global newborn screening market on the basis of product, technology, test type, and region:

Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments
• Reagents

Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Tandem Mass Spectrometry
• Pulse Oximetry
• Enzyme Based Assay
• DNA Assay
• Electrophoresis
• Others

Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Dry Blood Spot Test
• CCHD
• Hearing Screen

Newborn Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Order a free sample PDF of the Newborn Screening Market Intelligence Study, published by Grand View Research.